Low and Minimal-flow Anesthesia in Oral and Maxillofacial Surgery Patients: Which One is Ideal?
Akdeniz Medical Journal · 08.06.2026 · 12 (1)
DOI: 10.53394/akd.1652997 ↗Kurz gefasst
Fachartikel in der Zeitschrift Akdeniz Medical Journal, online erschienen am 08.06.2026. Verfasst von Fatih Oluş und 1 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Financial support & Sponsorship: None Conflicts of interest: None.
Abstract (Originalsprache)
ObjectiveLow and Minimal-flow Anesthesia, despite its advantages, including cost and pollution reduction and less heat/moisture loss, has limited prevalence due to concerns of complications and the need for closer monitoring. The objective of this study was to assess the benefits and risks of low- and minimal-flow anesthesia in patients undergoing oral and maxillofacial surgery.Material and MethodsConducted at Akdeniz University, 149 ASA 1-2 class patients were categorized into four Fresh Gas Flow (FGF) groups post-anesthesia induction. Data collected included vital signs, complications, operation and awakening times, and gas use.ResultsThere were no significant differences in demographics or ASA classification. However, variations in oxygen, air and sevoflurane use across the various FGF groups were identified (p
Förderung
- Financial support & Sponsorship: None Conflicts of interest: None
Zitieren
APA
Oluş, F., & Babun, H. (2026). Low and Minimal-flow Anesthesia in Oral and Maxillofacial Surgery Patients: Which One is Ideal?. Akdeniz Medical Journal, 12(1). https://doi.org/10.53394/akd.1652997
Vancouver
Oluş F, Babun H. Low and Minimal-flow Anesthesia in Oral and Maxillofacial Surgery Patients: Which One is Ideal?. Akdeniz Medical Journal. 2026;12(1). doi:10.53394/akd.1652997
BibTeX
@article{Olu2026,
author = {Oluş, Fatih and Babun, Hüseyin},
title = {Low and Minimal-flow Anesthesia in Oral and Maxillofacial Surgery Patients: Which One is Ideal?},
journal = {Akdeniz Medical Journal},
year = {2026},
volume = {12},
number = {1},
doi = {10.53394/akd.1652997}
}
EUVIMED